The Northwestern Medicine study in Nature Cancer demonstrates that blocking CysLTR1 with montelukast reprograms tumor-promoting neutrophils in mouse models of triple-negative breast cancer, melanoma, and other solid tumors, restoring sensitivity to checkpoint blockade. This preclinical work combines genetic knockout, pharmacologic inhibition, human immune cell assays, and retrospective analysis of patient datasets, yet lacks randomized controlled trial data and reports no specific sample sizes for the human tissue cohorts. Observational survival correlations show higher CysLTR1 expression linked to poorer outcomes, but causation remains unproven in prospective settings with potential industry conflicts unaddressed. Beyond the source, this mechanism connects to broader patterns of myeloid-derived suppressor cell plasticity seen in prior neutrophil-focused oncology research, such as studies on CXCR2 inhibitors that similarly shift myelopoiesis without depleting cells outright. The coverage underplays risks of long-term leukotriene blockade on systemic inflammation and overlooks combination dosing optimization needed to avoid off-target effects in immunocompromised patients. Synthesizing with related evidence from a 2023 Cancer Immunology Research paper on leukotriene signaling in breast cancer progression and a 2024 Nature Reviews Immunology overview of neutrophil heterogeneity, the approach offers a low-barrier path to trials but requires validation of biomarker-selected populations to confirm reprogramming efficacy over simple depletion strategies.